Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.
Product Specific References
*Chaudhary PM, Mechetner EB, Roninson IB: Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood. 1992 Dec 1;80(11):2735-9. [Abstract] [Full Text]
*Mechetner EB, Roninson IB: Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):5824-8. [Abstract] [Full Text]
*Goda K, Fenyvesi F, Bacsó Z, Nagy H, Márián T, Megyeri A, Krasznai Z, Juhász I, Vecsernyés M, Szabó G Jr: Complete inhibition of P-glycoprotein by simultaneous treatment with a distinct class of modulators and the UIC2 monoclonal antibody. J Pharmacol Exp Ther. 2007 Jan;320(1):81-8. [Abstract] [Full Text]
*Collnot EM, Baldes C, Schaefer UF, Edgar KJ, Wempe MF, Lehr CM: Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access. Mol Pharm. 2010 Jun 7;7(3):642-51. [Abstract]
*Kelley DJ, Pavelic ZP, Gapany M, Stambrook P, Pavelic L, Gapany S, Gluckman JL: Detection of P-glycoprotein in squamous cell carcinomas of the head and neck. Arch Otolaryngol Head Neck Surg. 1993 Apr;119(4):411-4. [Abstract]